Tiancheng Luo

Xuzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis.

Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis.

Journal: Autoimmunity
Published: January 27, 2026

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

Journal: Science advances
Published: January 02, 2026

Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.

Anti-BCMA/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial.

Journal: EClinicalMedicine
Published: August 06, 2025

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.

Journal: Annals of clinical and translational neurology
Published: July 11, 2025

A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.

A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.

Journal: Frontiers in immunology
Published: May 06, 2025

Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.

Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.

Journal: Frontiers in immunology
Published: February 19, 2025

Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.

Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.

Journal: Journal of neuroinflammation
Published: November 14, 2024

Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod: A Case Report.

Eculizumab as a Fast-Acting Therapy in a Myasthenic Crisis Patient With Poor Response to Efgartigimod: A Case Report.

Journal: The neurologist
Published: November 09, 2024

Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.

Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.

Journal: Journal of neurology
Published: February 28, 2024

Increased serum interleukin-41 correlates with disease severity in myasthenia gravis.

Increased serum interleukin-41 correlates with disease severity in myasthenia gravis.

Journal: International immunopharmacology
Published: February 07, 2024

Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.

Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.

Journal: Therapeutic advances in neurological disorders
Published: January 12, 2024

The non-oral infection of larval Echinococcus granulosus induces immune and metabolic reprogramming in the colon of mice.

The non-oral infection of larval Echinococcus granulosus induces immune and metabolic reprogramming in the colon of mice.

Journal: Frontiers in immunology
Published: October 31, 2022
Showing 1-12 of 13

Last Updated: 09/26/2026